<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>DARU Journal of Pharmaceutical Sciences</JournalTitle><Volume>9</Volume><Issue>1-2</Issue></Journal><ArticleTitle>"Pharmacodynamically evaluated bioequivalence of two preparations of Enalapril Maleate "</ArticleTitle><FirstPage>23</FirstPage><LastPage>27</LastPage><AuthorList><Author><FirstName></FirstName><LastName>"Tajerzadeh H</LastName></Author><Author><FirstName></FirstName><LastName>Hamidi M</LastName></Author><Author><FirstName></FirstName><LastName>Rouini MR</LastName></Author><Author><FirstName></FirstName><LastName>Shahverdi M</LastName></Author><Author><FirstName></FirstName><LastName>Ghaiumi A "</LastName></Author></AuthorList><History><PubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>06</Day></PubDate></History><Abstract>The bioequivalence of two preparations of enalapril maleate (20 mg tablets) manufactured in Iran has been exploited in reference to a standard preparation (Xanef 20 tablets, MSD, Germany) in 14 healthy volunteers. Following oral dosing of a single tablet of each of test and standard products, as a randomized crossover design with 10-day washout intervals, the blood samples were collected in predetermined time points and using a synthetic substrate, Hippuryl-Histidy-Leucine (HHL), the release of hippuric acid from the substrate was determined as Angiotensin-Converting-Enzyme (ACE) activity of serum fractions. The percent of ACE inhibition in each sample was calculated and plotted against time, from which three pharmacodynamic parameters, i.e. Emax, tmax and AUC0-24 were derived. The results of statistical comparison of these parameters showed that both of the test preparations are bioequivalent with reference standard preparation.</Abstract><web_url>https://daru.tums.ac.ir/index.php/daru/article/view/115</web_url><pdf_url>https://daru.tums.ac.ir/index.php/daru/article/download/115/115</pdf_url></Article></Articles>
